HER2 expression identifies dynamic functional states within circulating breast cancer cells
Circulating tumour cells in women with advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer acquire a HER2-positive subpopulation after multiple courses of therapy. In contrast to HER2-amplified primary breast cancer, which is highly sensitive to HER2-targeted therapy, the clinical significance of acquired HER2 heterogeneity during the evolution of metastatic breast cancer is unknown. Here we analyse circulating tumour cells from 19 wom...
Provenance — who produced it, who reused it
Linked to 5 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- SLC7A11 expression level dictates differential responses to oxid... 2023 · 313 cites
- Genomic hallmarks and therapeutic implications of G0 cell cycle... 2023 · 74 cites
3 further papers cite this accession but reuse could not be confirmed.
Deep data QC
88/100 · BStandardized, field-standard QC computed by touching the data — every metric states how it was obtained · evidence: measured
The B grade is a transparent weighted average. Each metric below scored from 0–100% against the published bulk-RNA-seq thresholds, weighted by its importance; nothing is hidden or subjective.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0